ST Pharm
ST Pharm
01
Who we are
02
Our record
03
Newsroom
04
Contact
En
Ko
ST Pharm
Science & Technology
Business Overview
CDMO
Small Molecule
Oligonucleotide
mRNA
CRO
AnaPath Research & Service
R&D
Virtual R&D
Global R&D
About
ST PHARM
Key Members
History
Global Approval
ST Pharm Family
CI
Public
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
Careers
ESG
Under construction
Social Responsibility Management
Human Rights
Environment, Safety & Health
Ethical and Compliance
Customer-Oriented
Social Contribution
Report
Governance
Sitemap
Linkedin
Public
IR Materials
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
IR Library
Disclosure Information
IR Materials
Notice
[Earning Call] 2025 1st Quarter Earning Call Presentation Material/Transcript
Apr 29, 2025
KIS Korea Investors Conference 2025
Feb 17, 2025
[Earning Call] 2024 4rd Quarter Earning Call Presentation Material
Feb 10, 2025
[Update] IR Material based on 3Q Quarterly Report
Nov 19, 2024
[IR Material] Macquarie Securities Korea NDR (Hong Kong / Singapore)
Nov 1, 2024
[Earning Call] 2024 3rd Quarter Earning Call Presentation Material
Nov 1, 2024
[IR Material] Korea Investment Week 2024
Sep 6, 2024
[IR Materials] mRNA Platform Technology
Mar 14, 2023
[Analyst Report] 4Q review: Oligo-driven strength
Feb 17, 2023
[Earnings Summary] ST PHARM 4Q. 2022 Earnings Summary
Feb 17, 2023
[Presentation] ST PHARM IR Preentation (Feb. 2023)
Feb 6, 2023
[Analyst Report] Fundamentals intact despite noise
Jan 16, 2023
[Analyst Report] Value of mRNA platform growing
Dec 16, 2022
[Analyst Report] 3Q disappoints as clients adjust production volume
Nov 1, 2022
2
of
3
We care about your privacy
This site uses essential cookies necessary for the operation of the service and for maintaining your language preferences. For more information, please review our
Privacy Policy
and
Terms of Service
.
Close
Accept
Decline